Hvivo Plc · LSE:HVO
Hvivo — Corporate Update (January 2026)
7 slides from Hvivo's corporate update, Jan 29, 2026
Slide 1: Trading Update
Trading Update January 2026 AIM: HVO
Slide 2: Disclaimer
Disclaimer The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engaging
Slide 3: Strong Strategic Progress in 2025
Strong Strategic Progress in 2025 Key Unaudited Financial Highlights c.£46.7m Positive low single digit c.£14.3m Revenue Adjusted EBITDA Margin* Cash 2024 : £62.7m 2024 : 26.2% 31 Dec 2024 : £44.2m Key Operational Highlights Completed strategic acquisitions Established integrated end-to-end early an
Slide 4: An Integrated Full-Service Early Phase CRO
An Integrated Full-Service Early Phase CRO Service Lines Consultancy Clinical Trials Human Challenge Trials Laboratories • Non-Clinical, clinical, CMC, PK • Phase I-II CRO services • Challenge model development • Standalone Laboratory Services • Data management, biostats • Phase II-III site services
Slide 5: Renewed Market Momentum
Renewed Market Momentum • Improving market sentiment Biopharma M&A Spend by Therapeutic Area4 • Relative stability in U.S. market Oncology US$146bn • >$300B patent cliffs between 2025-20301 CNS/Neurology US$83bn *Immunology and inflamation US$82bn • Renewed dealmaking and M&A momentum in 2025: CRO/C
Slide 6: Positioned to Return to Growth in 2026
Positioned to Return to Growth in 2026 Pipeline & Orderbook Key growth initiatives • Multiple preferred providerships secured Four key growth initiatives that will drive future revenue expansion : • Increasing momentum in sales pipeline across diversified therapeutic areas & service lines 1. Expand
Slide 7: Questions
Avivo Questions